Increasing trend of utilising active surveillance for Gleason Score 7 (3+4) prostate cancer

被引：2
|
作者：
Bernardino, Rui [1 ,4 ,6 ]
Sayyid, Rashid K. [1 ]
Leao, Ricardo [5 ]
Zlotta, Alexandre R. [1 ]
van Der Kwast, Theodorus [2 ]
Klotz, Laurence [3 ]
Fleshner, Neil E. [1 ]
机构：
[1] Univ Toronto, Div Urol, Dept Surg Oncol, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada
[3] Univ Toronto, Sunnybrook Hlth Sci Ctr, Div Urol, Toronto, ON, Canada
[4] Univ NOVA Lisboa, Fac Ciencias Med, NOVA Med Sch, Computat & Expt Biol Grp, Lisbon, Portugal
[5] Hosp Cuf, Coimbra, Portugal
[6] Univ Toronto, Princess Margaret Canc Ctr, 700 Univ Ave, Toronto, ON M5G 1Z5, Canada
来源：
BJU INTERNATIONAL | 2023年 / 132卷 / 06期
关键词：
D O I：
10.1111/bju.16162
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：638 / 640
页数：3
相关论文
共 50 条
  • [1] Are Men with Gleason Score 3+4=7 Cancer on Biopsy Candidates for Active Surveillance?
    Epstein, Jonathan I.
    Tosoian, Jeff
    MODERN PATHOLOGY, 2017, 30 : 223A - 223A
  • [2] Are Men with Gleason Score 3+4=7 Cancer on Biopsy Candidates for Active Surveillance?
    Epstein, Jonathan I.
    Tosoian, Jeff
    LABORATORY INVESTIGATION, 2017, 97 : 223A - 223A
  • [3] Using active surveillance for Gleason 7 (3+4) prostate cancer: A narrative review
    Bernardino, Rui
    Sayyid, Rashid K.
    Ledo, Ricardo
    Zlotta, Alexandre R.
    van der Kwast, Theodorus
    Klotz, Laurence
    Fleshner, Neil E.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2024, 18 (04): : 135 - 144
  • [4] Characteristics and outcome of prostate cancer patients with overall biopsy Gleason score 3+4=7 and highest Gleason score 3+4=7 or >3+4=7
    Verhoef, Esther I.
    Kweldam, Charlotte F.
    Kuemmerlin, Intan P.
    Nieboer, Daan
    Bangma, Chris H.
    Incrocci, Luca
    van der Kwast, Theodorus H.
    Roobol, Monique J.
    van Leenders, Geert J.
    HISTOPATHOLOGY, 2018, 72 (05) : 760 - 765
  • [5] Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer?
    Bhat, Abhishek
    Punnen, Sanoj
    Madueke, Ikenna
    Abern, Michael R.
    ONCOLOGY-NEW YORK, 2019, 33 (06): : 235 - +
  • [6] Prediction of pathologic upgrading in Gleason score 3+4 prostate cancer: Who is a candidate for active surveillance?
    Pham, Duc Minh
    Kim, Jung Kwon
    Lee, Sangchul
    Hong, Sung Kyu
    Byun, Seok-Soo
    Lee, Sang Eun
    INVESTIGATIVE AND CLINICAL UROLOGY, 2020, 61 (04) : 405 - 410
  • [7] Oncological outcomes in men on active surveillance with Gleason 3+4 prostate cancer
    Amin, A.
    Blazevski, A.
    Thompson, J.
    Stricker, P.
    BJU INTERNATIONAL, 2020, 125 : 86 - 86
  • [8] Using active surveillance in biopsy proven Gleason 3+4 prostate cancer
    Wong, Lih-Ming
    Tang, Vincent
    Corcoran, Niall
    Costello, Anthony
    BJU INTERNATIONAL, 2015, 116 : 17 - 18
  • [9] CONTEMPORARY PATIENTS WITH BIOPSY GLEASON 3+4 PROSTATE CANCER: ELIGIBILITY FOR ACTIVE SURVEILLANCE
    Kwon, Ohseong
    Lee, Hakmin
    Jo, Jung Ki
    Lee, Young Ik
    Oh, Jong Jin
    Lee, Sangchul
    Jeong, Seong Jin
    Byun, Seok-Soo
    Lee, Sang Eun
    Hong, Sung Kyu
    JOURNAL OF UROLOGY, 2015, 193 (04): : E515 - E515
  • [10] Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3+4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance
    Gearman, Derek J.
    Morlacco, Alessandro
    Cheville, John C.
    Rangel, Laureano J.
    Karnes, R. Jeffrey
    JOURNAL OF UROLOGY, 2018, 199 (05): : 1188 - 1195
12345